Many men with prostate cancer will develop hormonal resistance. There are now multiple treatment options that have been shown to modestly improve overall survival in the metastatic castrate-resistant prostate cancer (mCRPC) setting. There are numerous other exciting agents that will likely reach the market in the next few years.
|Original language||English (US)|
|Number of pages||6|
|Journal||Journal of Managed Care Medicine|
|State||Published - Jan 1 2014|
ASJC Scopus subject areas
- Health Policy